WP
TEVA icon

WealthPLAN Partners’s Teva Pharmaceuticals TEVA Stock Holding History

WealthPLAN Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-28
Closed -$211 – 1080
2023
Q2 		$211 Hold
28
– – ﹤0.01% 1211
2023
Q1 		$248 Buy
+28
New +$277 ﹤0.01% 1271
2016
Q3 		$22.2K Sell
491
-653
-57% -$34.1K 0.01% 466
2016
Q2 		$24.7K Buy
+1,144
New +$60.9K ﹤0.01% 1296
2015
Q4 		$92 Buy
+1,390
New +$85.9K ﹤0.01% 1637

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
SPC
Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

WealthPLAN Partners's TEVA Position: Q3 2023 in Review

WealthPLAN Partners sold out of Teva Pharmaceuticals (TEVA) in Q3 2023, closing a stake of 28 shares — an estimated $211 sold.

WealthPLAN Partners first reported a position in TEVA in Q4 2015 and held it in 5 quarters. The position peaked at $24.7K in Q2 2016. 435 funds tracked by Wall St. Rank hold TEVA as of Q3 2023.

  • WealthPLAN Partners reported no remaining Teva Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • WealthPLAN Partners sold 28 Teva Pharmaceuticals shares in Q3 2023, an estimated $211.
  • WealthPLAN Partners first reported a position in Teva Pharmaceuticals in Q4 2015 and held it in 5 quarters.
  • WealthPLAN Partners's Teva Pharmaceuticals position peaked at $24.7K in Q2 2016.
  • 435 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2023.

Based on WealthPLAN Partners's 13F filing for Q3 2023, filed 2 Nov 2023.